Summary
Diabetic patients have a high susceptibility to microvascular complications, atherosclerosis and thrombosis. Platelet hyperreactivity possibly related to an imbalance in arachidonic acid metabolism may be involved. Aortic rings or renal cortex produced a potent inhibitor of platelet aggregation, identified as prostacyclin (PGI2). Release of PGI2 by tissues from streptozotocin — diabetic rats (aorta: 0.07±0.1 ng/ mg wet weight; renal cortex 0.004±0.001 ng/mg wet weight) was significantly depressed when compared with controls (aorta: 0.26±0.07 ng/mg wet weight; renal cortex: 0.009±0.001 ng/mg wet weight). Treatment of diabetic animals with insulin for 8 days restored PGI2 production to normal. The finding that PGI2 is depressed in the aorta and in the kidney, tissues which develop angiopathy, and that this is normalised by insulin, suggests that impaired PGI2 production, perhaps associated with platelet hyperreactivity may play a role in the vascular complications of diabetes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Keen, H.: Glucose intolerance, diabetes mellitus and athersclerosis prospects for prevention. Postgrad. Med. J.52, 445–457 (1976)
Goodale, F., Daou, A. S., Florentin, R., Lee, K. T., Gittelsohn, A.: Chemico-anatomic studies of arteriosclerosis and throm bosis in diabetics. I. Coronary artery wall thickness, thrombosis and myocardial infarction in autopsied North Americans. Exp. Mol. Pathol.1, 352–363 (1962)
Heath, H., Brigden, W. D., Canever, J. V., Pollock, J., Hunter, P. R., Kelsey, J., Bloom, A.: Platelet adhesion and aggregation in relation to diabetic retinopathy. Diabetologia7, 308–315 (1971)
Halushka, P. V., Lurie, D., Colwell, J. A.: Increased synthesis of Prostaglandin — E — like material by platelets from patients with diabetes mellitus. N. Engl. J. Med.297, 1306–1310 (1977)
Harrison, H. E., Reece, A. H., Johnson, M.: Decreased vascular prostacyclin in experimental diabetes. Life Sci.23, 351–356 (1978)
Johnson, M., Reece, A. H., Harrison, H. E.: Decreased vascular prostacyclin in experimental diabetes. Adv. Pharmacol. Chemother.4, 865 (1979)
Barham, D., Trinder, P.: An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst97, 142–145 (1972)
Bunting, S., Moncada, S., Reed, P., Salmon, J. A., Vane, J. R.: An antiserum to 5, 6-dihydro prostacyclin (PGI1) which also binds prostacyclin. Prostaglandins15, 565–573 (1978)
Moncada, S., Gryglewski, R., Bunting, S., Vane, J. R.: A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins12, 715–736 (1976)
Dusting, G. J., Moncada, S., Vane, J. R.: Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coro nary arteries by arachidonic acid. Prostaglandins13, 3–15 (1977)
Kwaan, H. C., Colwell, J. A., Cruz, S., Suwanwela, N., Dobbie, J. G.: Increased platelet aggregation in diabetes mellitus. J. Lab. Clin. Med.80, 236–246 (1972)
Breddin, K., Grun, H., Krzywarek, H. R., Schremmer, W. P.: On the measurement of spontaneous platelet aggregation: the platelet aggregation test. III. Methods and first clinical results. Thromb. Haemostas.35, 669–691 (1976)
Ferguson, J. C., Mackay, N., Philip, J. A. D., Sumner, D. J.: Determination of platelet and fibrinogen half life with75 (Se) selenomethionine: studies in normal and diabetic subjects. Clin. Sci. Mol. Med.49. 115–120 (1975)
McGuire, M. B., Ward, J. D., Russell, R. G. G., Best, L. C., Preston, F. E.: Increased malonyldialdehyde productionin vitro by platelets from patients with diabetes mellitus. (Abstract), p. 531. XVII Congress of Haematology, Paris, July 1978
Preston, F. E., Ward, J. D., Marcola, B. H., Porter, N. R., Timperley, W. R., O'Malley, B. C.: Elevatedβ-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy. Lancet1978 I, 238–239
Needleman, P., Moncada, S., Bunting, S., Vane, J. R., Hamberg, M., Samuelson, B.: Identification of an enzyme in platelet microsomes which generates Thromboxane A2 from prostaglandin endoperoxides. Nature261, 558–560 (1976)
Hamberg, M., Samuelson, B.: Detection and isolation of an endoperoxide intermediate in prostaglandin synthesis. Proc. Natl. Acad. Sci. USA70, 899–903 (1973)
Herman, A. G., Moncada, S., Vane, J. R.: Formation of prostacyclin (PGI2) by different layers of the arterial wall. Arch. Int. Pharmacodyn. Ther.227, 162–163 (1977)
Needleman, P., Minkes, M., Raz, A.: Thromboxanes: Selective biosynthesis and distinct biological properties. Science193, 163–165 (1976)
Hamberg, M., Svensson, J., Samuelson, B.: Thromboxanes — a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci USA72, 2994–2998 (1975)
Szczeklik, A., Gryglewski, R. J., Wizankowki, R., Musial, J., Pieton, R., Mruk, J.: Circulatory and antiplatelet effects of intravenous prostacyclin in healthy men. Pharmacol. Res. Commun.10, 545–556 (1978)
Moncada, S., Gryglewski, R., Bunting, S., Vane, J. R.: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature263, 663–665 (1976)
Johnson, M., Harrison, H. E., Raftery, A. T., Elder, J. B.: Vascular prostacyclin may be reduced in diabetes in man. Lancet1979 I, 325–326
Ross, R., Glomset, J., Kariya, B., Harker, L.: A platelet dependent factor that stimulates the proliferation of arterial smooth muscle cellsin vitro. Proc. Natl. Acad. Sci. USA71, 1207–1210 (1974)
Tennenbaum, J., Nies, A. S., Aulsebrook, K., Sweetman, B., Oates, J. A.: Release of prostaglandins from rat renal papilla in vitro: Effect of glucose concentration. Fed. Proc.35, 223 (1976)
Praag, D. V., Farber, S. J.: Effect of increased osmolality on prostaglandin metabolism in rabbit kidney. Fed. Proc.35, 223 (1976)
Fox, C. S., Darby, S. C., Ireland, J. T., Sönksen, P. H.: Blood glucose control and glomerular capillary basement membrane thickening in experimental diabetes. Br. Med. J.1977 II, 605–607
Engerman, R., Bloodworth, J. M. B., Nelson, S.: Relationship of microvascular disease in diabetes to metabolic control. Diabetes26, 760–769 (1977)
Scharp, D., Krupin, T., Waltman, S., Oestrich, C., Feldman, S., Ballinger, W., Becker, B.: Relationship of abnormal insulin release to fluorophotometry in experimental diabetes. Diabetes27, 435 (1978)
Kohner, E. M., Fraser, T. R., Joplin, G. F., Oakley, N. W.: The effect of control on diabetic retinopathy. In: The treatment of diabetic retinopathy. Goldberg. M. F., Fine, S. L. (Eds.), p. 119–124. Washington: US Public Health Service No. 1890 1969
Takazakura, E., Nakamoto, Y., Hayakawa, H., Kawai, K., Muramoto, S., Yoshida, K., Shimizu, M., Shinoda, A., Takeuchi, J.: Onset and progression of diabetic glomerulopathy. Diabetes24, 1–9 (1975)
Mauer, S. M., Barbara, J., Vernier, R. L., Kjellstrand, C. M., Buselmeier, T. J., Simmons, R. L., Najarian, J. S., Goetz, F. C.: Development of diabetic vascular lesions in normal kidneys transplanted into patients with diabetes mellitus. N. Engl. J. Med.295, 916–920 (1976)
Author information
Authors and Affiliations
Additional information
Department for antiserum to prostacyclin and to Mrs. T. E. Robinson, Mr. M. J. A. Arnstein, Mrs. S. Jones and Miss S. Bowden for technical assistance.
Rights and permissions
About this article
Cite this article
Harrison, H.E., Reece, A.H. & Johnson, M. Effect of insulin treatment on prostacyclin in experimental diabetes. Diabetologia 18, 65–68 (1980). https://doi.org/10.1007/BF01228305
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01228305